Related Articles
Novel strategies in the treatment of castration-resistant prostate cancer (Review)
External beam radiation for the treatment of castration‑resistant prostate cancer following primary hormonal therapy with androgen ablation: Analysis and outcome of 21 patients
Identification of favorable subgroups for alternative anti‑androgen therapy in castration‑resistant prostate cancer
Risk stratification of castration‑resistant prostate cancer patients treated with cabazitaxel
Conversion to monotherapy with luteinizing‑hormone releasing hormone agonist or orchiectomy after reaching PSA nadir following maximal androgen blockade is able to prolong progression‑free survival in patients with metastatic prostate cancer: A propensity score matching analysis